<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49147">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466412</url>
  </required_header>
  <id_info>
    <org_study_id>P2M-PK-04-JP</org_study_id>
    <secondary_id>P2M-PK-04-JP</secondary_id>
    <nct_id>NCT02466412</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetic Profile of the CHTP 1.1 M</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the pharmacokinetic (PK)
      profiles of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon
      Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M) compared to menthol conventional cigarette
      (mCC) in healthy smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of the maximum concentration (Cmax) of nicotine following single use of CHTP 1.1 M and mCC</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of the area under the plasma concentration versus time curve from time zero (pre-product use) to last time point [AUC(0-last)] following single use of CHTP 1.1 M and mCC</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CHTP 1.1 M)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day -1 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = Wash-out
Day 3 = 2nd intervention (single product use of CHTP 1.1 M).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHTP 1.1 M</intervention_name>
    <description>Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)</description>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mCC</intervention_name>
    <description>Single use of of subject's own menthol conventional cigarette (mCC)</description>
    <arm_group_label>CHTP 1.1 M then mCC</arm_group_label>
    <arm_group_label>mCC then CHTP 1.1 M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Japanese.

          -  Subject is at a minimum 23 years of age.

          -  Smoking, healthy subject as judged by the Investigator.

          -  Subject has smoked for at least the last 3 years

          -  Subject smoked at least 10 commercially available mCCs per day over the last 4 weeks.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of a drug
             (whichever is longer) which has an impact on CYP2A6 activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fumimasa Nobuoka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ageo Medical Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ageo Medical Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>362-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 16, 2015</lastchanged_date>
  <firstreceived_date>May 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>nicotine absorption</keyword>
  <keyword>modified risk tobacco product</keyword>
  <keyword>conventional cigarette</keyword>
  <keyword>Carbon Heated Tobacco Product</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
